Polaryx Therapeutics, Inc. Common Stock
PLYX
Get informed when a big investor buys or sells
+ FollowMarket Cap$102.68M
Close$
$0.11
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $102.68 Million |
|---|---|
| Enterprise Value | $91.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.19 |
| Beta | -9.19 |
| Outstanding Shares | 48,278,370 |
Return
| Return on Equity | -62.61% |
|---|---|
| Return on Assets | -57.98% |
| Return on Invested Capital | -47.75% |
Valuation & Multiples
| P/E Ratio | -16.93 |
|---|---|
| PEG | -45.87 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -17.45 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.80%▲ 4.80% |
|---|---|
| Total Invested | $17.14M |
| Investors Holding | 14▲ 14.00% |
ESG Score
No data
About Polaryx Therapeutics, Inc. Common Stock
11 employees
CEO: Alex Yang Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement...